- Home
- CHRS vs SCPH Comparison
CHRS vs SCPH Comparison
Compare CHRS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SCPH
- Stock Information
- Founded
- CHRS 2010
- SCPH 2013
- Country
- CHRS United States
- SCPH United States
- Employees
- CHRS N/A
- SCPH N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- SCPH Health Care
- Exchange
- CHRS Nasdaq
- SCPH Nasdaq
- Market Cap
- CHRS 84.2M
- SCPH 173.6M
- IPO Year
- CHRS 2014
- SCPH 2017
- Fundamental
- Price
- CHRS $0.75
- SCPH $3.86
- Analyst Decision
- CHRS Buy
- SCPH Strong Buy
- Analyst Count
- CHRS 3
- SCPH 3
- Target Price
- CHRS $4.68
- SCPH $14.00
- AVG Volume (30 Days)
- CHRS 1.3M
- SCPH 267.3K
- Earning Date
- CHRS 08-07-2025
- SCPH 08-13-2025
- Dividend Yield
- CHRS N/A
- SCPH N/A
- EPS Growth
- CHRS N/A
- SCPH N/A
- EPS
- CHRS N/A
- SCPH N/A
- Revenue
- CHRS $272,251,000.00
- SCPH $41,982,000.00
- Revenue This Year
- CHRS N/A
- SCPH $108.95
- Revenue Next Year
- CHRS $106.56
- SCPH $73.83
- P/E Ratio
- CHRS N/A
- SCPH N/A
- Revenue Growth
- CHRS 19.87
- SCPH 138.10
- 52 Week Low
- CHRS $0.66
- SCPH $1.94
- 52 Week High
- CHRS $2.43
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- CHRS 44.78
- SCPH 52.65
- Support Level
- CHRS $0.72
- SCPH $3.77
- Resistance Level
- CHRS $0.82
- SCPH $4.14
- Average True Range (ATR)
- CHRS 0.04
- SCPH 0.18
- MACD
- CHRS 0.01
- SCPH -0.05
- Stochastic Oscillator
- CHRS 33.21
- SCPH 32.97
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.